BioStock: Staybe Therapeutics sees optimism amongst study clinics

During 2020, Stayble Therapeutics, despite the Covid-19-pandemic, managed to initiate a phase IIb study with its candidate STA363 in all the countries intended to be included in the study. The company also carried out an IPO and a successful issue which was subscribed to 436 per cent. In addition, the results from Stayble Therapeutics’ studies with STA363 were published in Spine, a leading scientific journal in the area of spinal research. BioStock has contacted Stayble Therapeutics’ CEO Andreas Gerward to find out more about the past year and the company’s plans for 2021.

Read the full article at biostock.se:

https://www.biostock.se/en/staybe-therapeutics-sees-optimism-amongst-study-clinics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se